

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/076818 A1

(51) International Patent Classification:

A61K 31/4174 (2006.01) A61K 9/00 (2006.01)
A61K 45/06 (2006.01)

cut 06511 (US). **POSTMA, Friso**; c/o BioXcel Therapeutics, Inc., 555 Long Wharf Drive, New Haven, Connecticut 06511 (US).

(21) International Application Number:

PCT/US2021/054171

(74) Agent: **BROWN, Fraser** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, District of Columbia 20004 (US).

(22) International Filing Date:

08 October 2021 (08.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/089,135 08 October 2020 (08.10.2020) US

(71) Applicant: **BIOXCEL THERAPEUTICS, INC.**
[US/US]; 555 Long Wharf Drive, New Haven, Connecticut 06511 (US).


(72) Inventors: **Yocca, Frank**; c/o BioXcel Therapeutics, Inc., 555 Long Wharf Drive, New Haven, Connecticut 06511 (US). **RISINGER, Robert**; c/o BioXcel Therapeutic, Inc., 555 Long Wharf Drive, New Haven, Connecticut 06511 (US). **DE VIVO, Michael**; c/o BioXcel Therapeutics, Inc., 555 Long Wharf Drive, New Haven, Connecticut 06511 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: TREATMENT OF BIPOLAR DISORDERS AND PSYCHOSIS USING DEXMEDETOMIDINE HYDROCHLORIDE

Figure 1: Improvement in YMRS scale in bipolar disorder patients at 24 hours following administration of 180 µg dexmedetomidine hydrochloride sublingual film. Asterisks showed significance versus placebo at 24 hours. *p< 0.05; ** p< 0.01 and *** p< 0.005



(57) Abstract: Disclosed herein are methods and composition for treating bipolar disorders and psychosis by administering dexmedetomidine. The methods and composition alleviate mania, hypomania, psychosis, and depression in the subjects, providing improved therapeutic outcomes.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*